Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alpha-interferon · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Gemcitabine, Docetaxel, 5FU, Oxaliplatin | DRUG | Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation |
| Alpha-interferon | BIOLOGICAL | Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy |
| Abdominal/pelvic radiation therapy | RADIATION | 3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46 |
| Pancreaticoduodenectomy | PROCEDURE | Surgery performed if subject is considered candidate by protocol definition. |
Inclusion Criteria: * Biopsy proven adenocarcinoma of the pancreas * Tumor must be radiographically bidimensional by abdominal/pelvic CT * Cancer must be locally advanced and not considered immediately treated by standard surgical procedure * No prior therapy for pancreas cancer Exclusion Criteria...
Top 20 of 63 competitors